4 completed, 2 withdrawn, 1 active not recruiting, 1 recruiting. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Withdrawn 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
Follow Germ Cell Tumors: new trials by email Literature Review of Germ Cell Tumors trials Research Report on Germ Cell Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate - B-Cell Lymphoma, Myelodysplastic Syndromes (MDS) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2022-11-01 | 2026-08-07 |
| Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa, Azacytidine - Sarcomas, Melanomas | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2021-12-14 | 2021-12-17 | |
| Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors Nivolumab - Germ Cell Tumors | Phase 2 | Withdrawn | Hospital Beatriz Ângelo | 2018-10-01 | 2019-08-21 | |
| Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Brentuximab Vedotin - Germ Cell Tumors, Testis Cancer | Phase 2 | Terminated | Nabil Adra | 18 | 2016-03-09 | 2019-12-10 |
| Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Paclitaxel, Ifosfamide, Cisplatin - Germ Cell Tumors | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 92 | 2013-06-01 | 2026-08-06 |
| Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors Pazopanib - Germ Cell Tumors, Measurable Disease | Phase 2 | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 43 | 2013-05-17 | 2021-05-14 |
| Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis Paclitaxel, Ifosfamide, Carboplatine - Germ Cell Tumors | Phase 2 | Completed | Institut Claudius Regaud | 101 | 2009-03-13 | 2026-04-14 |
| Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy Recombinant Human Thrombopoietin - Germ Cell Tumors, Hepatic Cancer | Phase 1 / Phase 2 | Completed | St. Jude Children's Research Hospital | 40 | 2000-06-01 | 2008-04-10 |
| Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors Cyclophosphamide, Etoposide, Cisplatin - Testicular Neoplasms, Germ Cell Tumors | Phase 2 | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1996-12-01 | 2014-06-12 |
Neoplasms, Germ Cell and Embryonal (9) · Testicular Neoplasms (3) · Carcinoma, Embryonal (1) · Carcinoma, Renal Cell (1) · Hodgkin Disease (1) · Jacobs syndrome (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Plasma Cell (1) · Liver Neoplasms (1) · Lymphoma, B-Cell (1) · Melanoma (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neuroblastoma (1)
Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (5) · Male Urogenital Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Genital Diseases (3) · Genital Diseases, Male (3) · Genital Neoplasms, Male (3) · Gonadal Disorders (3) · Testicular Diseases (3) · Disease Attributes (2) · Hematologic Diseases (2)
Etoposide (3) · Bleomycin (2) · Carboplatin (2) · Cisplatin (2) · Cyclophosphamide (2) · Ifosfamide (2) · Paclitaxel (2) · Azacitidine (1) · Brentuximab Vedotin (1) · Cytapheresis (1) · Mesna (1) · Nivolumab (1) · Thrombopoietin (1) · bintrafusp alfa protein, human (1) · fludarabine (1)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Hospital Beatriz Ângelo (1) · Institut Claudius Regaud (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Nabil Adra (1) · National Cancer Institute (NCI) (1) · St. Jude Children's Research Hospital (1)
United States (5) · Italy (2) · France (1) · Portugal (1)
Andrea Necchi, MD (1) · Costantine Albany, MD (1) · Darren Feldman, MD (1) · David Marin, MD (1) · David S Schrump, M.D. (1) · Najat C. Daw, M.D. (1)